177 related articles for article (PubMed ID: 38333008)
1. Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database.
Xia S; Li YF; Raschi E; Zhang BK; Noguchi Y; Sarangdhar M; Yan M; Ma JA
Front Pharmacol; 2024; 15():1275814. PubMed ID: 38333008
[No Abstract] [Full Text] [Related]
2. Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.
Xia S; Gong H; Wang YK; Liu L; Zhao YC; Guo L; Zhang BK; Sarangdhar M; Noguchi Y; Yan M
Front Pharmacol; 2023; 14():1129730. PubMed ID: 37007042
[No Abstract] [Full Text] [Related]
3. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
4. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
[TBL] [Abstract][Full Text] [Related]
5. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
7. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.
Barbieri MA; Russo G; Sorbara EE; Cicala G; Franchina T; Santarpia M; Speranza D; Spina E; Silvestris N
Front Oncol; 2023; 13():1268672. PubMed ID: 38023143
[TBL] [Abstract][Full Text] [Related]
9. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
11. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
Zhang Y; Fang Y; Wu J; Huang G; Bin J; Liao Y; Shi M; Liao W; Huang N
Front Pharmacol; 2022; 13():817662. PubMed ID: 35431928
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
15. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
[TBL] [Abstract][Full Text] [Related]
16. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wei Q; Wu X
Front Pharmacol; 2022; 13():986357. PubMed ID: 36408225
[No Abstract] [Full Text] [Related]
17. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
[No Abstract] [Full Text] [Related]
18. Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database.
Chow JW; Yan MM; Zhao H; Li ZR; Zhang Q; Zhong MK; Qiu XY
Expert Opin Drug Saf; 2023; 22(5):433-441. PubMed ID: 36334066
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.
Kwon OC; Lee HS; Yang J; Park MC
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38243710
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
